Asthma is a common chronic airway inflammatory disease that affects both pediatric and adult population, and is associated with significant morbidity, mortality, and financial burden worldwide. One of the main concerns with asthma is the manifestation of irreversible tissue remodeling of the airways due to the chronic inflammatory environment that will eventually disrupt the whole structure of the airways. Majority of the asthma patients are treated with corticosteroids. However, the development of steroid resistance is a commonly encountered issue, which will limit the treatment options for these patients. Biological therapies are a promising therapeutic approach for this subclass of patients. Interleukin 5 is recently gaining a lot of attention as a biological target capable of ameliorating the tissue remodeling process. SinceIL-5-neutralizing monoclonal antibodies (Mepolizumab, Reslizumab, Benralizumab) are currently available for clinical use, this review aims to revisit the role of IL-5 in asthma pathogenesis at large and airway remodeling in particular, in addition to exploring its role as a target for biological treatments.